October Biosciences launches FIRST water-soluble transdermal cannabinoid delivery system

DENVER - Nov. 3, 2019 - PRLog -- October Biosciences, a laboratory specializing in novel cannabinoid transport systems has announced the launch of it's first product, nCBD Transdermal Gel, the ONLY product on the market with the company's unique water-soluble transdermal cannabinoid delivery system.

The October Biosciences team is led by Founder & CEO David Foggy and Chief Technology Officer Dr. Thomas L. Henshaw, who have invested over four years of research and development into the technology for the delivery system, which enables users of the product to experience a faster and 5 times (5x) stronger onset of the therapeutic properties of the CBD.

"I started October with the vision to provide the best cannabinoid products on the market with unmatched delivery and efficacy." said Founder & CEO, David Foggy.  "My team has spearheaded a lengthy Research and Development process to reach this monumentous goal and bring our Transdermal Gel to market. It's very exciting, to see our products in the hands of consumers, that are looking to shift their lives to the next level."

The nCBD Transdermal Gel is used by active adults, professional and amateur athletes, and other health focused persons that want a fast acting, highly effective natural alternative to "over the counter" pain and inflammation drugs.

About October Biosciences:

October Biosciences started in 2015 as Citizens Laboratories.  The company focus at the time was subcritical water extraction of high medicinal value cannabinoids from hemp biomass. The research and development combined with the team's backgrounds in Chemistry, Systems Engineering, and Product Development led to the creation of the nCBD Transdermal Gel.

About the Team:

David Foggy, Founder & CEO spent over a decade working for tech companies such as Sun Microsystems, Intel, Lockheed Martin, and SpaceX. David holds a BS from San Francisco State University and a PhD in Computation from the University of Manchester.

Dr. Thomas L. Henshaw, Chief Technology Officer, is an award-winning scientist and innovator. He holds a B.A. in Chemistry from the University of Colorado, Boulder and a PhD in Physical Chemistry from Denver University.   He has amassed over 25 years of specialized experience in a variety of scientific arenas including chemical kinetics, spectroscopy, laser development, bioanalytical chemistry, and biosensor development. Dr. Henshaw holds five U.S. patents.

For more information: http://www.octoberbio.com